Back to top
more

Guardant Health (GH)

(Real Time Quote from BATS)

$17.12 USD

17.12
825,665

-0.98 (-5.41%)

Updated Apr 25, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 400% and 1.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround

by Zacks Equity Research

Guardant Health (GH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Kevin Cook headshot

Bull of the Day: NeoGenomics (NEO)

by Kevin Cook

Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite

Guardant Health (GH) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Kevin Cook headshot

Bull of the Day: NeoGenomics (NEO)

by Kevin Cook

Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales

Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Believe Guardant Health (GH) Could Rally 42.09%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 46.40% and 6.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Does Guardant Health (GH) Have the Potential to Rally 39.77% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Guardant Health (GH) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -3.17% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down -6.66% in 4 Weeks, Here's Why You Should You Buy the Dip in Guardant Health (GH)

by Zacks Equity Research

Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Predict a 123.55% Upside in Guardant Health (GH): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Guardant Health (GH) points to a 123.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

How Much Upside is Left in Guardant Health (GH)? Wall Street Analysts Think 75.47%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 75.5% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 2.86% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -24.41% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?